Sotigalimab
Adenosquamous Carcinoma of the Pancreas
James Cleary, MD, PhDmonoclonal_antibodyPhase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 30/ 100
- Competitive Position
- 95/ 100
Competitive context
11 Active assets in the Adenosquamous Carcinoma of the Pancreas cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FLUOROURACILUM Revolution Medicines, Inc. | Phase 3 | BB |
Irinotecan Revolution Medicines, Inc. | Phase 3 | BB |
Daraxonrasib Revolution Medicines, Inc. | Phase 3 | B |
Zoldonrasib Revolution Medicines, Inc. | Phase 3 | B |
Eloxatin Revolution Medicines, Inc. | Phase 3 | B |
View all 11 →
Same molecule, other indications
Sotigalimab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →